Clinical trial readout dates for Madrigal Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 3 Resmetirom NASH; Cirrhosis, Liver · NCT05500222 | December 2026 Ongoing |
| Phase 3 Resmetirom Non-Alcoholic Fatty Liver Disease · NCT04951219 | March 2027 Ongoing |
| Phase 3 MGL-3196 NASH - Nonalcoholic Steatohepatitis · NCT03900429 | January 2028 Ongoing |
| Phase 2 Resmetirom MASH - Metabolic Dysfunction-Associated Steatohepatitis · NCT07335601 | August 2028 Recruiting |
| Phase 2 Resmetirom MASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis · NCT07763015 | July 2029 Recruiting |
Madrigal Pharmaceuticals Inc. reported $961M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). It reported net income of $55M for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-03 |